Back to Authors

Kassam, Zain

https://orcid.org/0000-0002-2183-2223

A5079523598 | I4210147203

Mayo Clinic

Finch Therapeutics (United States)

Citations 3

S145 Week 24 Efficacy and Safety Data from PRISM3: A Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S63-S64

10.14309/01.ajg.0000773052.38150.f9

S144 CP101 Engraftment Drives Efficacy: Results From a Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for Prevention of Recurrent C. difficile Infection

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S63-S63

10.14309/01.ajg.0000773048.24890.7e

S131 CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results From a Randomized, Placebo-Controlled Trial

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S57-S57

10.14309/01.ajg.0000772996.83378.7c